Fasken Martineau DuMoulin LLP advised the Underwriter in connection with Medexus Pharmaceuticals’s offering. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) closed its bought-deal public offering of 3,389,900...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here